Single-domain antibodies against hepatitis A viruses and derived proteins of single-domain antibodies

A hepatitis A virus and single-domain antibody technology, applied in the field of biotechnology or immunology, can solve problems such as poor repeatability, large differences in antibody affinity, and poor stability between production batches

Active Publication Date: 2020-05-12
REGENECORE BIOTECH CO LTD
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the test must be based on RT-PCR, and the detection cost is high; the SPA synergistic agglutination test utilizes the A protein (SPA) in the cell wall of Staphylococcus aureus to specifically bind to the Fc segment of HAV-IgG. Reverse indirect agglutination occurs when HAV-Ag is contained in
The sensitivity and specificity of this test are low, and the results are judged to be largely influenced by human factors, so it can only be used as a preliminary detection method when the equipment is limited; the general ELISA method uses the solid-phase carrier to adsorb immunologically active proteins. Add the serum of HAV antibody to be tested to the microplate of μ chain. If the serum to be tested is in the acute stage of hepatitis A infection, the IgM antibody in the serum will be captured by its antibody human μ chain antibody, then add the enzyme-la...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Single-domain antibodies against hepatitis A viruses and derived proteins of single-domain antibodies
  • Single-domain antibodies against hepatitis A viruses and derived proteins of single-domain antibodies
  • Single-domain antibodies against hepatitis A viruses and derived proteins of single-domain antibodies

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0073] Example 1: Construction of a single-domain antibody library against hepatitis A virus:

[0074] (1) Use 1ml of hepatitis A virus inactivated vaccine to immunize an Inner Mongolia Alxa Bactrian camel, once a week, a total of 7 consecutive immunizations, during which B cells are stimulated to express specific nanobodies; (2) After the immunization Finally, extract 100ml of camel peripheral blood lymphocytes and extract total RNA; (3) synthesize cDNA and use nested PCR to amplify VHH; (4) use restriction endonucleases Pst I and Not I to digest 20 μg pMECS phage display vector and 10 μg VHH and ligated the two fragments; (5) Transformed the ligated product into electroporation-competent cells TG1, constructed a phage display library for the capsid protein of hepatitis A virus and determined the storage capacity, the size of the library storage capacity was about 2×10 9 ; At the same time, the correct insertion rate of the target fragment in the built library was detected by...

Embodiment 2

[0075] Embodiment 2: the expression of hepatitis A virus capsid protein:

[0076] (1) The sequence information of the hepatitis A virus capsid protein was found from the protein database of NCBI (AccesionNumber: P08617.1); (2) After Uniprot analysis, VP2-VP3-VP1 was selected as the target expression fragment; (3) Add kozak enhancer sequence (5'-GGATCGAACCCTT-3') and IgG kappa signal peptide (METDTLLLWVLLLWVPGSTGD) at the 5' end of VP2-VP3-VP1, and add 6*His tag fusion expression at the 3' end; (4) Examples of use The scheme described in 8 carries out eukaryotic expression; (5) purify with reference to the scheme described in Example 9 using nickel column affinity chromatography; (6) carry out SDS-PAGE analysis with reference to the method of Example 9, and determine that the protein purity is at 95 % or more, and the concentration is more than 0.5mg / mL, keep it at low temperature for later use.

Embodiment 3

[0077] Example 3: Screening for single domain antibodies against hepatitis A virus:

[0078] (1) Take 200 μL of recombinant TG1 cells to culture in 2×TY medium, add 40 μL of helper phage VCSM13 to infect TG1 cells during the period, and culture overnight to amplify phages, use PEG / NaCl to precipitate phages the next day, and centrifuge to collect amplified phages ; (2) NaHCO diluted in 100mM pH 8.3 3 500ug of neutravidin protein in the medium was coupled to the microtiter plate, placed overnight at 4°C, and a negative control well was set up at the same time; (3) the next day, 100 μL of biotin-labeled hepatitis A virus capsid protein (VP2- VP3-VP1-Biotin), incubate at room temperature for 2 hours, add 100 μL PBS to the negative control well; (4) After 2 hours, add 100 μL of 3% skim milk, and block at room temperature for 2 hours; (5) After the end of blocking, add 100 μl amplification Post-phage library (approximately 2×10 11 phage particles) at room temperature for 1 h; (6)...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to the technical field of biotechnology or immunology and relates to single-domain antibodies against hepatitis A virus and derived proteins of the single-domain antibodies. An amino acid sequence of CDR1 of the single-domain antibodies is shown in any one of SEQ ID NO:83-SEQ ID NO:117; an amino acid sequence of CDR2 is shown in any one of SEQ ID NO:118-SEQ ID NO:143;and an amino acid sequence of CDR3 is shown in any one of SEQ ID NO:144-SEQ ID NO:174. Beneficial effects are that: the traditional method for indirect detection of hepatitis A virus antigen (HAV-Ag)by detecting hepatitis A virus antibodies (HAV-IgM and HAV-IgG) has many detection steps and many influence factors. The present invention provides a detection method based on ELISA that directly detects the hepatitis A virus antigen (HAV-Ag) without RT-PCR.

Description

technical field [0001] The invention relates to the technical field of biotechnology or immunology, and relates to a single-domain antibody against hepatitis A virus and its derivative protein. Background technique [0002] Antibody (Ab) or Immunoglobulin (Ig) is a type of glycoprotein in blood and tissue fluid, which is produced by plasma cells that proliferate and differentiate after receiving antigen stimulation from B cells. It mainly exists in body fluids such as serum and can It specifically binds to the corresponding antigen and is an important effector molecule that mediates humoral immunity. In addition to mediating specific humoral immune responses as important effector molecules, antibodies play an important role in the prevention and treatment of diseases, especially infectious diseases. Behring won the Nobel Prize in Medicine and Physiology for creating serum therapy. Since then, antibodies artificially prepared by polyclonal, monoclonal and genetically enginee...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K16/10G01N33/569
CPCC07K16/1009G01N33/56983C07K2317/565G01N2333/10C07K2317/569C07K2319/30Y02A50/30
Inventor 苏志鹏姚尧王乐飞
Owner REGENECORE BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap